Kaoru Tanaka

8.8k total citations · 1 hit paper
112 papers, 3.7k citations indexed

About

Kaoru Tanaka is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Kaoru Tanaka has authored 112 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Oncology, 52 papers in Pulmonary and Respiratory Medicine and 24 papers in Molecular Biology. Recurrent topics in Kaoru Tanaka's work include Lung Cancer Treatments and Mutations (44 papers), Lung Cancer Research Studies (20 papers) and Cancer Immunotherapy and Biomarkers (19 papers). Kaoru Tanaka is often cited by papers focused on Lung Cancer Treatments and Mutations (44 papers), Lung Cancer Research Studies (20 papers) and Cancer Immunotherapy and Biomarkers (19 papers). Kaoru Tanaka collaborates with scholars based in Japan, United States and Malaysia. Kaoru Tanaka's co-authors include Kazuhiko Nakagawa, Hidetoshi Hayashi, Hiroyasu Kaneda, Masayuki Takeda, Koji Haratani, Kazuto Nishio, Yasutaka Chiba, Kimio Yonesaka, Ryoji Kato and Yoshikazu Hasegawa and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Kaoru Tanaka

104 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

2017 726 citations Koji Haratani, Hidetoshi Hayashi et al. profile →

Peers

Kaoru Tanaka

ONCOL

PRM

IMMUN

Shiu‐Feng Huang Taiwan

Mona F. Melhem United States

Stefano Pepe Italy

Toru Kumagai Japan

Masahiko Nishiyama Japan

Robert D. Loberg United States

Shunchang Jiao China

Marie Brevet France

Angelo Raffaele Bianco Italy

Gurkamal Chatta United States

Shiu‐Feng Huang Taiwan

Kaoru Tanaka

1.2k ×0.5

ONCOL

944 ×0.7

PRM

1.4k ×1.3

596 ×1.3

275 ×0.7

IMMUN

Citations per year, relative to Kaoru Tanaka Kaoru Tanaka (= 1×) peers Shiu‐Feng Huang

Countries citing papers authored by Kaoru Tanaka

Since Specialization

Citations

This map shows the geographic impact of Kaoru Tanaka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaoru Tanaka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaoru Tanaka more than expected).

Fields of papers citing papers by Kaoru Tanaka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kaoru Tanaka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaoru Tanaka. The network helps show where Kaoru Tanaka may publish in the future.

Co-authorship network of co-authors of Kaoru Tanaka

This figure shows the co-authorship network connecting the top 25 collaborators of Kaoru Tanaka. A scholar is included among the top collaborators of Kaoru Tanaka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kaoru Tanaka. Kaoru Tanaka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ohta, Ryuichi, Yoshinori Ryu, Kaoru Tanaka, Chiaki Sano, & Hidetoshi Hayashi. (2025). Initial symptoms and diagnostic delay in immune checkpoint inhibitor-related adrenal insufficiency: a systematic review and meta-ethnography of case reports. Frontiers in Endocrinology. 16. 1636452–1636452.

Ohta, Ryuichi, Nobuyuki Yamamoto, Kaoru Tanaka, Chiaki Sano, & Hidetoshi Hayashi. (2025). Clinical Characteristics and Outcomes of SMARCA4-Mutated or Deficient Malignancies: A Systematic Review of Case Reports and Series. Cancers. 17(16). 2675–2675.

Ohta, Ryuichi, Yoshinori Ryu, Kaoru Tanaka, Chiaki Sano, & Hidetoshi Hayashi. (2025). Peritoneal Metastasis in Non-Small Cell Lung Cancer: A Systematic Review of Clinical Features, Molecular Profiles, Diagnostic Approaches, and Outcomes. Cancer Management and Research. Volume 17. 2127–2141.

Fujita, Yoshihiko, Hiromichi Matsuoka, Yasutaka Chiba, et al.. (2024). Dual single‑nucleotide polymorphism biomarker combination for opioid selection to treat cancer pain. Molecular and Clinical Oncology. 22(2). 14–14. 1 indexed citations

Kurosaki, Takashi, Kenji Chamoto, Shinichiro Suzuki, et al.. (2023). The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study. Frontiers in Immunology. 14. 1325462–1325462. 12 indexed citations

Saito, Yuki, Akihiro Homma, Naomi Kiyota, et al.. (2022). Human papillomavirus-related oropharyngeal carcinoma. Japanese Journal of Clinical Oncology. 52(7). 700–706. 2 indexed citations

Haratani, Koji, Hidetoshi Hayashi, Shigeki Shimizu, et al.. (2020). Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer. Clinical Cancer Research. 26(8). 2037–2046. 172 indexed citations

Haratani, Koji, Kimio Yonesaka, Shiki Takamura, et al.. (2019). U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. Journal of Clinical Investigation. 130(1). 374–388. 59 indexed citations

Sakai, Kazuko, Masayuki Takeda, Shigeki Shimizu, et al.. (2019). A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing. Scientific Reports. 9(1). 11340–11340. 10 indexed citations

10.

Fujisaka, Yasuhito, Takayasu Kurata, Kaoru Tanaka, et al.. (2014). Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors. Investigational New Drugs. 33(2). 380–388. 37 indexed citations

11.

Tanizaki, Junko, Isamu Okamoto, Takafumi Okabe, et al.. (2012). Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer. Clinical Cancer Research. 18(22). 6219–6226. 126 indexed citations

12.

Hayashi, Hidetoshi, Takayasu Kurata, Yasuhito Fujisaka, et al.. (2012). Phase I trial of OTS11101, an anti‐angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor. Cancer Science. 104(1). 98–104. 16 indexed citations

13.

Kaneda, Hiroyasu, Tokuzo Arao, Kaoru Tanaka, et al.. (2010). FOXQ1 Is Overexpressed in Colorectal Cancer and Enhances Tumorigenicity and Tumor Growth. Cancer Research. 70(5). 2053–2063. 157 indexed citations

14.

Kudo, Kanae, Tokuzo Arao, Kaoru Tanaka, et al.. (2010). Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In Vivo. Clinical Cancer Research. 17(6). 1373–1381. 31 indexed citations

15.

Okamoto, Kunio, Isamu Okamoto, Wataru Okamoto, et al.. (2010). Role of Survivin in EGFR Inhibitor–Induced Apoptosis in Non–Small Cell Lung Cancers Positive for EGFR Mutations. Cancer Research. 70(24). 10402–10410. 75 indexed citations

16.

Tamura, Daisuke, Tokuzo Arao, Kaoru Tanaka, et al.. (2010). Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition. Cancer Science. 101(6). 1403–1408. 48 indexed citations

17.

Matsumoto, Kunio, Tokuzo Arao, Kaoru Tanaka, et al.. (2009). mTOR Signal and Hypoxia-Inducible Factor-1α Regulate CD133 Expression in Cancer Cells. Cancer Research. 69(18). 7160–7164. 114 indexed citations

18.

Matsumoto, Kunio, Hideyuki Yokote, Tokuzo Arao, et al.. (2008). N‐Glycan fucosylation of epidermal growth factor receptor modulates receptor activity and sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor. Cancer Science. 99(8). 1611–1617. 75 indexed citations

19.

Yamaguchi, Shuichi, Maki Hasegawa, Shiro Aizawa, et al.. (2004). DNA-dependent protein kinase enhances DNA damage-induced apoptosis in association with Friend gp70. Leukemia Research. 29(3). 307–316. 4 indexed citations

20.

Higa, Kazuo, et al.. (1983). HERPETIC PAIN AND CELLULAR-IMMUNITY. Acta Anaesthesiologica Scandinavica. 27. 71. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact